Matilde Saggese

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.

Journal: Targeted oncology

Published: January 27, 2021

Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.

Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.

Journal: Clinical lung cancer

Published: September 02, 2020

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Journal: The New England journal of medicine

Published: November 22, 2019

Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA.

Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: August 02, 2019

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 05, 2019

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer.

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer.

Journal: Breast cancer research : BCR

Published: January 29, 2019

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset.

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: July 18, 2018

Complexity of FGFR signalling in metastatic urothelial cancer.

Complexity of FGFR signalling in metastatic urothelial cancer.

Journal: Journal of hematology & oncology

Published: September 20, 2015

Patients' perceptions of research biopsies in phase I oncology trials.

Patients' perceptions of research biopsies in phase I oncology trials.

Journal: Oncology

Published: July 02, 2014

Research biopsies in the context of early phase oncology studies: clinical and ethical considerations.

Research biopsies in the context of early phase oncology studies: clinical and ethical considerations.

Journal: Oncology reviews

Published: April 22, 2013

Advanced gastric cancer: is there enough evidence to call second-line therapy standard?

Advanced gastric cancer: is there enough evidence to call second-line therapy standard?

Journal: World journal of gastroenterology

Published: July 19, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026